Drug Safety

, Volume 40, Issue 6, pp 475–482 | Cite as

Pharmacovigilance of Regenerative Medicine Under the Amended Pharmaceutical Affairs Act in Japan

Leading Article

Abstract

Two Japanese regulatory agencies, the Ministry of Health, Labour and Welfare and the Pharmaceuticals and Medical Devices Agency announced the implementation of a new review system called ‘Conditional Approval,’ specifically for the emerging field of regenerative medicine, in an amendment to the Pharmaceutical Affairs Act in 2014. Regenerative medicine was regulated in the category of ‘Medical Devices’ prior to the amendment and was not covered by the Relief Service, a system that provides financial aid to people who have experienced an adverse drug reaction and developed serious side effects as a result. Through the amendment, regenerative medicine is defined as a new category and is covered by the Relief Service under the amended Pharmaceutical Affairs Act, called the ‘Act on Securing Quality, Efficacy and Safety of Pharmaceuticals, Medical Devices, Regenerative and Cellular Therapy Products, Gene Therapy Products, and Cosmetics’ (PMD Act). This amendment allows the use of Relief Service data for pharmacovigilance activities, making the Relief Service the third adverse drug reaction reporting route in addition to the existing reporting routes from marketing authorization holders and healthcare providers. For optimum incorporation and use of this Relief Service data, earlier access should be allowed even before the reports from the Pharmaceuticals and Medical Devices Agency to the Ministry of Health, Labour and Welfare are finalized, which is mandatory under the current PMD Act.

References

  1. 1.
    Pharmaceutical Affairs Law. Law No. 145 of 10 August; 1960 (in Japanese).Google Scholar
  2. 2.
    The Law on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices (Law No. 145 of 10 August, 1960), Final Revision: Law No. 50 of 26 June; 2015 (in Japanese).Google Scholar
  3. 3.
    US Food and Drug Administration. Human cells, tissues, and cellular and tissue-based products, 21CFR1271; 2012. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=1271&showFR=1. Accessed 14 Dec 2016.
  4. 4.
    Regulation (EC) No. 1394/2007 of the European Parliament and of the Council of 13 November 2007 on Advanced Therapy Medicinal Products and amending Directive 2001/83/EC and Regulation (EC) No. 726/2004.Google Scholar
  5. 5.
    Noriko M. Yakujieisei no rekishiteki hensen to yakugaku kyoiku (in Japanese). Nihon Ishigaku Zasshi. 2008;54(3):305–6.Google Scholar
  6. 6.
    Secretariat, Cabinet. Japan revitalization strategy: Japan is back, 14 June, 2013. http://www.kantei.go.jp/jp/singi/keizaisaisei/pdf/en_saikou_jpn_hon.pdf. Accessed 13 Nov 2016.
  7. 7.
    Secretariat, Cabinet. Healthcare policy, 22 July, 2014. http://www.kantei.go.jp/jp/singi/kenkouiryou/suisin/ketteisiryou/dai2/siryou1.pdf. Accessed 13 Nov 2016.
  8. 8.
    Ministry of Health, Labour and Welfare. Regulatory strategy initiative, 26 June, 2015. http://www.mhlw.go.jp/file/04-Houdouhappyou-11121000-Iyakushokuhinkyoku-Soumuka/0000089691.pdf. Accessed 13 Nov 2016.
  9. 9.
    Final Report of the Committee for Investigation of Drug-Induced Hepatitis Cases and Appropriate Regulatory Administration to Prevent Recurrence of Drug-induced Suffering (in Japanese), 28 April, 2010. http://www.mhlw.go.jp/shingi/2010/04/dl/s0428-8a.pdf. Accessed 13 Nov 2016.
  10. 10.
    Ministry of Health, Labour and Welfare. The summary of the amendment of PAL in 2014 (in Japanese). http://www.mhlw.go.jp/file/06-Seisakujouhou-11120000-Iyakushokuhinkyoku/0000066816.pdf. Accessed 13 Nov 2016.
  11. 11.
    Yano K, Tsuyuki K, Watanabe N, et al. Regulatory approval for autologous human cells and tissue products in the United States, the European Union, and Japan. Regener Ther. 2015;1:45–56.CrossRefGoogle Scholar
  12. 12.
    Pharmaceuticals and Medical Devices Agency. Review report (brand name: JACE), 6 August 2007. https://www.pmda.go.jp/files/000153389.pdf. Accessed 13 Nov 2016.
  13. 13.
    Pharmaceuticals and Medical Devices Agency. Review report (brand name: JACC), 22 June, 2012. https://www.pmda.go.jp/files/000203221.pdf. Accessed 13 Nov 2016.
  14. 14.
    Takeshi S. Yakujihou kaisei no shinchoku joukyou. PDA J GMP Valid Japan. 2003;5(2):65–9.Google Scholar
  15. 15.
    Konomi K, Tobita M, Kimura K, Sato D. New Japanese initiatives on stem cell therapies. Cell Stem Cell. 2015;16(4):350–2.CrossRefPubMedGoogle Scholar
  16. 16.
    Hara A, Daisaku S, Yasuyuki S. New governmental regulatory system for stem cell-based therapies in Japan. Ther Innov Regul Sci. 2014;48:681.CrossRefGoogle Scholar
  17. 17.
    Pharmaceuticals and Medical Devices Agency. Profile of services (in Japanese). http://www.pmda.go.jp/relief-services/outline/0001.html. Accessed 13 Nov 2016.
  18. 18.
    Pharmaceuticals and Medical Devices Agency. Profile of services (in Japanese). https://www.pmda.go.jp/relief-services/adr-sufferers/0007.html. Accessed 13 Nov 2016.
  19. 19.
    The Act on Pharmaceuticals and Medical Devices Agency, Independent Administrative Agency (Law No. 192 of 20 December, 2002), Final Revision; Law No. 69 of 13 June, 2014 (in Japanese).Google Scholar
  20. 20.
    Pharmaceuticals and Medical Devices Agency. “What are Relief Systems?”. https://www.pmda.go.jp/files/000200353.pdf. Accessed 11 Dec 2016.
  21. 21.
    Pharmaceuticals and Medical Devices Agency. Midterm plan (in Japanese). http://www.pmda.go.jp/files/000209845.pdf. Accessed 11 Dec 2016.
  22. 22.
    Ministry of Health, Labour and Welfare. Minutes of committee on regenerative medicines and biological products (in Japanese), 2 September, 2015. Ahttp://www.mhlw.go.jp/stf/shingi2/0000114609.html. Accessed 11 Dec 2016.
  23. 23.
    Pharmaceuticals and Medical Devices Agency. Review report (brand name: HeartSheet), 6 August, 2007 (in Japanese). http://www.pmda.go.jp/regenerative_medicines/2015/R20151008001/470034000_22700FZX00002_A100_2.pdf. Accessed 13 Nov 2016.
  24. 24.
    Press Release made by Terumo Corporation. Terumo receives approval for the manufacturer and sale of its HeartSheet autologous skeletal myoblast sheets in Japan, 18 September, 2015. http://www.terumo.com/about/pressrelease/2015/20150918.html. Accessed 13 Nov 2016.
  25. 25.
    Pharmaceuticals and Medical Devices Agency. Format to claim medical expenses by Relief Service (in Japanese). https://www.pmda.go.jp/PmdaSearch/youshikiDownload/singleFileDownload/f_yosiki1%25docx. Accessed 13 Nov 2016.
  26. 26.
    Pharmaceuticals and Medical Devices Agency. Outcome of claims on the Relief Service (in Japanese). https://www.pmda.go.jp/relief-services/adr-sufferers/0036.html. Accessed 13 Nov 2016.
  27. 27.
    Sipp D. Conditional approval: Japan lowers the bar for regenerative medicine products. Cell Stem Cell. 2015;16(4):353–6.CrossRefPubMedGoogle Scholar
  28. 28.
    Stem the tide. Nature. 2015;518:163–4.Google Scholar
  29. 29.
    Pharmaceuticals and Medical Devices Agency. Conditional approval for regenerative medicines, 25 November, 2014. https://www.pmda.go.jp/files/000199506.pdf. Accessed 13 Nov 2016.
  30. 30.
    Ministry of Health, Labour and Welfare. Report for the establishment of public patient registry system (in Japanese). http://www.mhlw.go.jp/file/05-Shingikai-11121000-Iyakushokuhinkyoku-Soumuka/0000050196.pdf. Accessed 13 Nov 2016.
  31. 31.
    Hideki M, Kurokawa T. Involvement of anticancer drugs in the relief system for adverse drug reactions in Japan. Jpn J Clin Oncol. 2013;43(12):1273–81.CrossRefGoogle Scholar
  32. 32.
    European Medicines Agency. Guideline on safety and efficacy follow-up: risk management of advanced therapy medicinal products, 20 November, 2008. http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/10/WC500006326.pdf. Accessed 12 Dec 2016.
  33. 33.
    Food and Drug Administration. Investigating and reporting adverse reactions related to human cells, tissues, and cellular and tissue-based products (HCT/Ps) regulated solely under Section 361 of the Public Health Service Act and 21 CFR Part 1271 Guidance for Industry, March 2016. http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Tissue/UCM434834.pdf. Accessed 12 Dec 2016.
  34. 34.
    Food and Drug Administration. Guidance for industry current good tissue practice (CGTP) and additional requirements for manufacturers of human cells, tissues, and cellular and tissue-Based products (HCT/Ps), December 2011. http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Tissue/UCM285223.pdf. Accessed 12 Dec 2016.

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  1. 1.The University of Tokyo, Research Center for Advanced Science and TechnologyTokyoJapan

Personalised recommendations